Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (NASDAQ: IMAB) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer and autoimmune diseases. This page provides investors and industry professionals with timely updates on the company’s clinical trials, strategic partnerships, and operational developments.
Access consolidated news about IMAB’s innovative pipeline, including therapies targeting CD73 (uliledlimab) and Claudin 18.2 (givastomig). Stay informed on milestones across all development phases, from preclinical research to late-stage trials, with verified updates on regulatory progress and collaborative agreements.
Key content includes earnings reports, clinical data disclosures, licensing deals, and management commentary. All materials are sourced directly from company filings and official communications to ensure accuracy.
Bookmark this page for streamlined tracking of IMAB’s advancements in immuno-oncology and autoimmune research. Regular updates provide critical insights into the company’s progress in addressing unmet medical needs through differentiated biologics.
I-Mab (NASDAQ: IMAB) has announced accelerated progress in its Phase 1b givastomig study, with completed enrollment in the first dose expansion cohort ahead of schedule and continued momentum in the second cohort. The study evaluates givastomig, a Claudin 18.2 x 4-1BB bispecific antibody, for first-line gastric cancer treatment.
The Phase 1b program consists of a dose escalation study (n=17) and a dose expansion study (n=40). Topline data from the dose escalation study is expected in 2H 2025, while results from the 40-patient dose expansion study are anticipated in 1H 2026.
The study aims to assess givastomig's safety, preliminary efficacy, and pharmacokinetics in combination with standard care (nivolumab plus chemotherapy). Early data shows encouraging results, with the drug demonstrating activity across various CLDN18.2 expression levels and favorable tolerability when combined with chemotherapy and anti-PD-1 checkpoint inhibitors.
I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on precision immune-oncology agents for cancer treatment, has announced its participation in the Leerink Partners Global Healthcare Conference. The conference will take place in Miami, Florida on March 11-12, 2025, where I-Mab's management team will engage in one-on-one meetings with conference attendees.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents for cancer treatment, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The virtual conference is scheduled for February 11-12, 2025.
The company's management team will deliver a presentation on Tuesday, February 11, 2025, from 4:00 to 4:30 PM ET. The presentation will be accessible via webcast, and the company will also participate in one-on-one meetings during the conference.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology, announced that Wei Fu, the Chairman of the Board, plans to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) in open market transactions. These purchases will be executed via his controlled entity, although the exact number of ADSs and the timeframe for acquisition remain uncertain.
Wei Fu stated that the Board and senior leadership successfully executed the corporate strategy for 2024, aligning with the long-term goal of increasing shareholder value. The company recently prioritized its portfolio, designating givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, as its lead clinical program. Data from a dose escalation study combining givastomig with nivolumab and chemotherapy are expected in early H2 2025, with a 40-patient dose expansion study data anticipated in early 2026.
The company's current cash runway extends into 2027.
I-Mab (NASDAQ: IMAB) has announced a strategic portfolio prioritization focusing on givastomig, its lead clinical program targeting first-line metastatic gastric cancers. The company has completed enrollment for a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, with data expected in early H2 2025.
A 40-patient dose expansion study is ongoing with results anticipated in early 2026. The company's cash balance of $184.4 million (as of September 30, 2024) is expected to support operations into 2027.
Phase 1 trials showed an overall response rate of 16.3% (7/43) for givastomig monotherapy, with favorable safety profiles. The company is pausing the development of uliledlimab to focus resources on givastomig, while maintaining its partnership with ABL Bio for ragistomig development.
I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company focused on cancer immunotherapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York from December 3-5, 2024. The company's management team will deliver a presentation on December 4 at 4:30 p.m. ET. Key participants include CEO Sean Fu, CMO Phillip Dennis, CFO Joseph Skelton, and Senior Director of IR Tyler Ehler. The event will feature one-on-one and small group meetings during December 3-4. A webcast of the presentation will be accessible through the company's IR website.
I-Mab (NASDAQ: IMAB) reported Q3 2024 financial results and pipeline updates. The company ended Q3 with $184.4 million in cash and equivalents, expecting runway into 2027. Key developments include the appointment of Dr. Sean Fu as permanent CEO and encouraging clinical data for givastomig presented at ESMO 2024. The company reported a net loss from continuing operations of $20.5 million for Q3 2024. R&D expenses were $4.5 million, down from $5.1 million in Q3 2023. The company is preparing for a Phase 2 study of uliledlimab in first-line mNSCLC, with first patient dosing expected in 1H 2025.
I-Mab (NASDAQ: IMAB) has appointed Sean Fu, PhD, MBA as permanent Chief Executive Officer effective November 1, 2024, following his interim CEO role since July 15, 2024. Dr. Fu brings over 20 years of life sciences industry experience, including roles as Operating Partner at ABio-X, co-founder and CEO of RVAC Medicines, and Group VP at Luye Pharma Group. He previously spent 15 years at Merck & Co., managing late-stage clinical portfolio finances and leading R&D network integration following the $42 billion Merck-Schering-Plough merger. Dr. Fu holds a PhD from Ohio State University and an MBA from Wharton.
I-Mab (NASDAQ: IMAB) announced it will release its Q3 2024 financial results on November 14, 2024, before the US market opens. The company will not hold a conference call for Q3 results but plans to host an investor update call with its full-year 2024 results, where it will discuss its clinical pipeline, corporate strategy, and objectives. Financial results and related information will be available on the company's website.
I-Mab (NASDAQ: IMAB) announced it will present Phase 1 optimized dose estimation data for givastomig (TJ033721/ABL111) at SITC 2024. The presentation focuses on this novel first-in-class Claudin18.2 and 4-1BB bispecific antibody for cancer treatment. The poster presentation, numbered 1474, will take place on November 9, 2024, at the George R. Brown Convention Center in Houston, Texas, during the Society for Immunotherapy of Cancer conference. The poster details optimal dose estimation using an integrated approach from Phase 1 data and will be available on I-Mab's website under the 'Innovation, Publications & Presentations' section.
FAQ
What is the current stock price of I-Mab (IMAB)?
What is the market cap of I-Mab (IMAB)?
